Aclaris Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Aclaris Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2018 to Q3 2024.
  • Aclaris Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $14.8M, a 63.7% decline year-over-year.
  • Aclaris Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2024 was $73.4M, a 49% decline year-over-year.
  • Aclaris Therapeutics, Inc. annual Costs and Expenses for 2023 was $129M, a 7.53% increase from 2022.
  • Aclaris Therapeutics, Inc. annual Costs and Expenses for 2022 was $120M, a 24% increase from 2021.
  • Aclaris Therapeutics, Inc. annual Costs and Expenses for 2021 was $96.5M, a 68.1% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $73.4M $14.8M -$26M -63.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $99.4M $15.6M -$18.1M -53.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $117M $21.3M -$11.1M -34.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $129M $21.6M -$15.2M -41.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $144M $40.9M +$967K +2.42% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $143M $33.7M +$11.2M +49.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $132M $32.4M +$12.1M +59.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $120M $36.8M +$12.4M +51% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $107M $39.9M +$17.9M +81.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $89.2M $22.5M +$2.69M +13.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $86.5M $20.4M -$9.95M -32.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $96.5M $24.4M +$9.25M +61.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $87.2M $22M +$10M +84.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $77.2M $19.8M +$6.4M +47.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $70.8M $30.3M +$13.4M +79.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $57.4M $15.1M +$7.67M +103% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $49.7M $11.9M -$11.9M -50% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $61.7M $13.4M -$42.2M -75.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $104M $16.9M -$11.4M -40.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $115M $7.47M +$6.72M +894% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $109M $23.8M +$1.39M +6.18% Jul 1, 2019 Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $107M $55.7M +$20M +56.1% Apr 1, 2019 Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $87.2M $28.3M -$3.75M -11.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $90.9M $751K Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $22.5M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $35.7M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $32.1M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.